Capmatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CAPMATINIB |
|---|---|
| Type | Drug |
| Aliases | TabrectaКапматініб |
| Status | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | MET-selective TKI |
|---|---|
| Mechanism | Selective inhibitor of MET (c-MET) tyrosine kinase. GEOMETRY mono-1: ORR ~68% in 1L MET ex14-mutant NSCLC. |
| Typical dosing | 400 mg PO BID with food. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Indicated for MET ex14 skipping mutation NSCLC. Tepotinib alternative.
Used By
Regimens
REG-CAPMATINIB-NSCLC- Capmatinib monotherapy (GEOMETRY mono-1) — MET ex14 NSCLC